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A nov~tl method for diseovcr~¢ of HIV.I pretense itlhibitors in complex biological saml~ICs has been dcvdoped, The assay' is based on two sr+¢~i[~c 
reatlcnts: n recombinant protein constituted hy a portion of the HIV.I Ge l  polyprolitn comprisln,M th¢ pl?,-p24 cleavage site, fused to E. ¢¢d1 
//.~',llactosid~lse, und n monoclonal antibody' which binds the fusion prolein in the GaLl rellion. OindinB or.'~urs only if the fusion protein has not 
been cleaved by tltc HIV-I protease. The assay has been =tdupte¢l for the screenin~ or htrLie numbers of samples in st~nd=trd t,)6.well microliter 
plates. Usintl this r~ethod ubout 12000 microbial fermentation broths h~tve been tested and s~veral HIV, I pretense inhibitor), activities have been 
detccled. One or these has b~en studied in detail. 
Human imn~unodeficiency virus: Proteinase: Fusion protein: ImmunoloBical ussuy~ Microbitd alknlinc protea~ inhibitor 
I, INTRODUCTION 
There is growing interest in developing specific in- 
hibitors of the HIV.I aspartyl pretense as possible 
therapeutic agents in the treatment of AIDS [1,2]. 
Several different HIV-I pretense assays, based either on 
HPLC separations [3-7] or on chronaophoric [8,9], 
fluorogenic [10-12] or radiolabeled [13-15] synthetic 
peptides have been developed in various laboratories to 
test a variety of compounds for inhibitory activity. 
The 3D structure of the HIV-I pretense has recently 
been determined [16-18] and many investigators have 
made extensive use of the rational approach to design 
substrate analogs with specific inhibitory activity 
[19-23]. This has led to peptide derivatives which are 
potent inhibitors, but often suffer major drawbacks, 
e.g. scarce solubility in aqueous solutions, poor cell 
permeability, very rapid in vivo degradation, all factors 
causing serious limitations in bid-availability. As a con- 
sequence, there is at the present time a renewed interest 
in the screening of natural products for novel, possibly 
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Abbreviations: HIV-I, human immunodeficiency virus type-l; 
HPLC, high performance liquid chromatography; IPTO, isopropyl- 
/3D-thiogalactoside; PMSF, phenylmethylsulphonyl fluoride; d-ME, 
~-mercaptoethanoh TPEG, p-aminophenyl.~D-thiogalactoside; 
SDS-PAGE. sodium dodecyl sulfate polyacrylamide gel dec- 
trophoresis; IVIES, 2-(N-morpholino)ethane-sulphonic acid; BSA, 
bovine serum albumin; PBS, phosphate-bufferecl sa ine; PNPG, p- 
nitrophenyl-~D-galactosid¢; MAb, monoclonal antibody; ~.MAPI, 
co-microbial alkaline protease inhibitor, 
non. peptidic molecules which could display comparable 
inhibitory activity against HIV.I protease and, at the 
same time, more if=teresting in vivo properties. In addi- 
tion, in a random screening it is possible to discover in- 
hibitors of dimer formation, a process which appears to 
be required for full HIV-I protease activity [16-19,24]. 
With this tn mind, we have used a biotechnology ap- 
proach to develop an assay which is particularly 
suitable for the detection of HIV.I protease inhibitors 
in large nuntoers of samples. The assay has been used to 
screen microbial fermentation broths and several in- 
hibitory activities have been found. 
2. MATERIALS AND METHODS 
2,1, HIV.I pretense 
Recombinant E, cots expressing HIV.I pretense was kindly provid. 
ed by Dr B. Harris [24]. For screening of fermentation broths the en- 
zyme was routs t~ely used as a crude preparation [24]. Briefly. after in- 
duction and harvesting, cells (50 g) were resuspended in 100 ml of 10 
mM Tris.HCI buffer, pl-I 7,5, I mM EDTA, I mM DTT, I mM PMSF 
and 0,05% Triton X-10,0, sonicated and centrifuged at 10 000 x g for 
20 ram, HIV-I protease activity in E, colt extracts was assayed by 
cleavage of a synthetic heptapeptide substrate and HPLC analysis of 
proctucts (C. Tarnus. MMRDI, Strasbourg, personal communica- 
tion), essentially as described 13]. A corresponding extract from E. 
coli cells lacking rite HIV-I protease xpression vector was employed 
for controls, 
2.2. Expression and purification of gal-gugl lO 
The HindllI-Hindlll fragment from bp 631 to 1258 of HIV-I gag 
DNA [25] was subcloned into the unique Hindlll site of pUCI9 (Gib- 
ed BRL). From the resulting construct he Pstl-Pstl fragment con- 
taining 8 bp from the IPUCI9 polylinker (Pstl-Hindlli) fused to the 
Hindlll-Pstl fragment from bp 631 to 961 of HIV.I DNA, was 
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I~olattd and Inserled into Ih< uniq.¢ P#tl She or pURl91 [2&l, Thlt 
Save platmld pGA22 In which the/tax fragment i~ fated in frame ta 
the er~d of the I#¢Z gtn¢ to encode a fusion protein. The structure of 
tills 'llal-llallllO' ruslon protein It. depleted in Fit=. I, 
/~', ¢o//JMIOg(pG.A2;]) was grown at 37'C I11 Lurid Broth in the 
presence of, JO ~g/ml amptcillln. At ODdm=~ OJ IPTG (I raM) was 
added and after 2 h bacteria were Ilarvest~d and rcsuspended in I/';~0 
volume or :50 mM Trts.HCI, pH 8, :50 mM NaCI I mM EDTA (Burrer 
A), =ontainins 0,1 ram PMSF, I mM ben~amidine.HCI, O,I M 
arginin¢ and I mg/ml lysczyme. After 30 rain at 4"C cells were 
disrupted by sonttation and eemrtfuged for IO rain at 2~ 000 x g. Tl~e 
pellet was washed twice witl~ Buffer A containing 70 rnM ~, 
mertaptoethanol C~.ME) and 0,O~% Tritot= X.100 and then 
resuspended in O,I M Tris.HCI pH 7.8, 0,1 M NaCI, I ram MgCIh 
0.S mM EDTA. 70 mM #.ME IBuffer BL containing 8 M urea, AFter 
eentrlf,ugatlon (20 rain at ~0 000 x .~), lisa supernntant was adjusted 
to ~ M urea by dih, tion with Bur,far B; titan extensively tlialy~ed 
against Buffer B without i~-ME, At,tinily thromutograph:t on TPEG. 
Sepharos¢ was perforated essenlially as described [271, Protein 
purification was cl~etked by SDS-PAGE ttsin~ the PHAST.GEL 
syslefll (Pharmacia, Sweden), 
2.3. Prod.ellen of M..tb IGI2 
BAL.B/c mice were immunized i,p. with $0/=S or gal-gagl 0 at days 
- 60, - 42, - 30 and - I ~1, At day - 3 mice were boosted i.v. with the 
same protein, Spleen cells were fused witl~ Sp2/O.Agi4 mouse 
myeloma cells and hybridoma supernatants were screened b>' ELISA 
tecnniques for antibodies against gal-gagl I0 which did nol bind ~- 
galactosidase, Clone IGI2 was isolated and subcloned by limiting 
dilution technique, MAb IGI2 was identified as IgG~ using tile 
Mouse-Typer Sub.isotyping Panel (Bid-Rag). A western Blot analysis 
confirmed thai MAb I G 12 binds gal-gag110 with no detectable cross- 
reactivity with d-galactosldase, 
2.4, hmmmoassay for detection of HIP'./pretense inhibitors 
After removal of microbial cells by centrifugation, 5/,I of' fermenta- 
tion broth were mixed In 96.well microther plates with 45 .I of 0,25 
M MES/NaOH buffer, pH 6.0, 0, I M NaCI, 0,6070 w/v BSA 0,0ZS% 
v/v Twten 20, I mM sodium EDTA, 5 ~g/ml leupeptin, I mM PMSF 
and 1070 v/v E. colt extract containing recombinant HIV.I protease 
(section 2,1), After l0 rain of pre.incubation atroom temperature to
allow binding of a putative inhibitor to the viral enzyme, 25 ,1 of 
gal-gag110 fusion protein (50 #g/ml) were added to the wens and the 
microtiter plates incubated at 370C for 40 rain, 50 .I of reaction mix- 
ture were then transferred from each well into the corresponding well 
of a flat-bottom icrotiter plate pre-coated with MAb IG 12, 
These plates were coated by incubating 50 al of MAb IGI2 (50 
zg/ml in PBS) per well overnight at 250C, Unreacted protein binding 
sites were blocked by incubation with 3% BSA in PBS (1 h, 25°C). 
Finally, wells were emptied, washed 4-5 times with PBS and pat-dried 
on paper towels. MAb IGl2-coated plat~-, were usually used freshly 
made. 
After addition of the reaction solutions, the MAb IGl2-coated 
plates were incubated for 2 h at 250C to allow the selective bindin g of 
the uncleaved gal-gagl 0 to the antibody. The solutions ~ere then 
discarded and the plates washed 4-5 times with PBS containing 0,05°70 
Tween 20, To quanmate the amount of uncleared gal-gagi 10, 240 
,d/well of I mll/ml PNPCI, a ~,llala¢loddase.H~elrl¢ thromolltnl~ 
substrata, In ~0 mM sodium phosphate buffer, pH '/.It, ~10 mM N~CI. 
I mM MiICi= and 10 mM ~f,MB were added and tilt piglet Incubated 
for I h a( 25'C, Finally, 60 ~l/well or 1 j M Na=CO) w~re ~ddtd la 
~top the d,Snlas'tosid,~¢ reaction and the absorbance ~t 40~ nm wa~ 
determined uslnll a Titertek Multtstan ~tltroplat¢ reader (Fl~w L~b(). 
3, RESULTS 
3, !, Production and characterization of gM-gaR/ lO 
In order to obtain an HIV.!  protease substrata which 
was specific and, at the same time, suitable for a simple 
solid-phase assay, a gen¢ coding for a fusion protein 
was constructed, The resulting protein was engineered 
to contain tl~e Aid =°° to Ala at° fragment from HIV. I  
Gag polyprotein (p55) fused to the carboxy-terminus of 
E. coil/~.galactosidas¢ (Fig. 1), The gag portion of this 
'gal-gagllO' fusion protein comprised the piT/p24 
HIV-!  protease cleavage site Tyr=~=-Pro m [25], while 
the ~-galactosidase portion provided an easily 
measurable nzymatic activity. 
E. coli JMI09 containing plasmid pGA22, in which 
the expression of the fusion gene was driven by the P~a¢ 
promoter, was induced with I mM IPTG during steady 
state growth, gai-gag110 protein accumulated in cells at 
concentrations that were estimated by Coomassie blue- 
stained SDS-PAGE to be as high as 40-50070 of total 
protein content (not shown). After cell lysis and cen- 
trifugation most of the fusion protein was found in the 
precipitate, from which it was solubilized and quan- 
titatively recovered with a denaturation-renaturation 
step, This procedure yielded a large amount of 
gal-gagl l0 (80-90o70 pure) which retained full /~- 
galactosidase activity and was routinely used for HIV, 1 
pretense assays of microbial fermentation broths. Pure 
gal-gag110 was obtained by affinity chromatography 
on TPEG.Sepharose, exploiting the binding properties 
of the B-galactosidase portion [27]. 
Fig. 2A shows the SDS-PAGE analysis of gal-gagl I0 
fusion protein before and after incubation with recom- 
binant HIV,I protease. As incubation time increases 
the intact protein of about 130 kDa (lane b) is gradually 
replaced by the cleaved product (about 120 kDa, lanes 
d and e), as expected from the loss of an 80-amino acid 
fragment (Fig. 1). The cleavage reaction is strongly in- 
hibited by pepstatin A (Fig. 2A, lane f), a known in- 
hibitor of HIV.1 protease [28,29]. 
HIV-1 protease 
cleavage Site 
trorn pUR292 from ;:)UC19 I 
poly,n~o, po.yH.ko, p17 V p24 
I, ,0=0 I " - ' -~ ' -~" - ' - ' ' ' [ I -  -=II-= ='d N~-1T~M~-T~/~'~V-w~o~G~-R~R~P-~G-~d[-(~-[~-~-~-D-K~J~ -`o~N~Y~f~P-|-v-~#~E~E-A-A[C~U 
B-galactos idase Gag portion 
116 ~Da 12 kDa 
Fig, t. Description of gal-gagl I0 fusion protein. 
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Fill, 2, Clear.lie or Iial-llalll l0 fusion protein by HIV.I pretense, (A) SDS.PAGE analyds. Renatured Bal'lgall110 (200 ,.ltl) was treated with I ,.I 
of crude HIV.I pretense preparation 1241 tn 100tA or 0,2 M MESINaOH buffer, pH 6,0, 50 mM NaCi, I ram DTT, I mM F.DTA and i mM 
PMSF at lIT*C, Lane=: (a) molecular mass standards, indicated in kDa; (b) Jal-llail110, non.treated; (¢) Ilal-=alll i0 treated for 60 rain with a crude 
e~,tract from £, .,//cell~ lacking the HIV.I prose=ca expression vector (control); (.d) anti (e) ~,al-llalll IO treated with HIV.I  pretense for 30 and 
60 rain respe¢lively; (13 same at (el, but in the presence of 0,5 mM pepltatin A (Cnlblochem), SDS.PACE was performed in a Pha~;l Syltem up. 
parntt=s (Pharmacla), usin= 7,SFo acrylamid¢ lids, #.ME as reducintt ajent and Coom=~si¢ blue for staining. (B) Westcrrt Blot analysis of the came 
tie| ttsintl atl anti.i~.italact0sidase mono¢lonat antibody {Boehrinller Mannhelm, Germany) followed by anti.mouse AuroProbe BL (Janssen, 
Belgium), Lane order as in (A), {C) Western Blot analysis of the sa me llel usin= an anti,p24 polyclonal antibody (BIochrom, Germarty) and anti. 
sheep AuroProbe I l l .  Lane order as in (AI, Botl~ immunoblots were treated ~ith Intense BI. sliver enhaneenaem kit Oanssen). 
i 
A Western Blot analysis with two different antibodies 
confirms the identity of the protein bands, As expected, 
an anti-/3.galactosidase antibody recognizes both 
uncleared and cleaved gal-gagl 0 (Fig. 2B), while an 
anti.p24 polyclonai antibody binds only to the uncieav- 
ed protein (Fig, 2C), since in the cleaved fusion the p24 
portion has been cut off  by HIV.I pretense, 
3.2, Characterization of  MAb 1G12 
The gal-gagll0 fusion protein was used as im- 
munogen to produce monoclonal antibodies. MAb 
1(312, was selected for its ability to recognize the intact 
antige~ but not /3-galactosidase, as indicated by both 
EL1SA and Western Blot experiments (not shown). 
When MAb 1(312 was analyzed with a Western Blot 
of a total HIV-I l~sate, containing all viral proteins, on- 
ly the Gag precursor, p55, was recognized (Fig. 3). 
Neither p24 or pit  were bound by the antibody. This in- 
dicates that the epitope recognized by MAb IGI2 is In- 
deed localized in the Gag portion of gal-gag110, but is 
destroyed upon cleavage by HIV-I pretense. This 
strongly suggests that the HIV-I protease cleavage site 
is comprised in such an epitope region. 
Experiments with MAb IG12 immobilized on 
microtiter wells confirmed that the antibody binds only 
uncleared and not HIV-I protease-cleaved gal-gagll0. 
In addition, its binding affinity was found to be suitable 
for an ELISA-type immunoassay, as indicated by the 
observation that the amount of bound antigen was not 
significantly reduced after repeated washing cycles. 
3.3. Screening of microbial metabolites for HIY. I  
pretense inhibitors 
Using recombinant HIV-1 pretense, gal-gagllO fu- 
sion protein and MAb IGI2, a solid.phase im- 
munoassay was devised to test microbial metabolites 
fo r  H IV -1  protease inhib i tors  (see section 2 for descr ip-  
t ion  of the assay), 
ab 
160 - 
65 -  
55-  
4] [ -43  -~ 
32-  
24-  
18-  I 
Fig. 3. Characterization f MAb IGI2 by V~restern Blot analysis of 
total HIV-I proteins, Novapath Immunoblot strips (Bio-Rad, R|ch- 
mend) were used. Lanes: (a) human serum (l:100 dil.) from an AIDS 
patient followed by anti-human AuroProbe BL (Janssen); (b) MAb 
IGI2 (I #g/m[) and anti-mouse AuroProbe BL (Janssen), In both 
cases silver enhancement (IntenSE BL, Janssen) was performed. 
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Fig, 4. (A] Chemical structure of or.MAP| [3l], (B) Dose-response 
plot showing the inhibition of cleavage of gel-gaUl 10 by HIV-I pro. 
tease observ¢d in the presence or the indicated concentrations or (x) 
~.MAPI or (o) pepstatin A (Calbiochern). The assay w~ performed 
essentially as described in section Z, in the pretence of 5=7o DMSO, 
Determinations were from ~wo separate xperiments. 
With this detection system about 12 000 fermentation 
broths were tested for the presence of H IV. I  proteasc 
inhibitors. These broths were derived mostly from Ac- 
tinomycetes genera or fungal isolates. About 0.25°70 of 
them were found to contain significant and reproduci- 
ble inhibitory activities against the viral enzyme, 
Among these activities one which showed good stability 
even after 1 h of incubation with horse or bovine serum 
was selected and the protease inhibitor was purified and 
characterized, The chemical structure determination 
allowed its identificatior., as a peptide derivative of 
known structure, previously named a-microbial 
alkalis-, protease inhibitor, or ,-,-MAPI (Fig. 4A) 
[30,31]. Fig, 4B shows the inhibition of the HIV-1 pro- 
tease reaction observed at different concentrations of~- 
MAPI and pepstatin A. These two natural products 
display similar dose-response curves with 50070 inhibi- 
tion of substrata cleavage observed at 2,0 v.M ~x-MAPI 
and 4.5/~M pepstatin A. 
4. DISCUSSION 
A novel solid-phase immunoassay has been 
developed to detect HIV-I protease inhibitors in large 
mzmbers of biological samples. For such purpose the 
system described is fast and efficient and it has been us- 
ed to screen about 12 000 fermentation broths. The 
most interesting aspect of this method is the ability to 
detect he presence of an HIV-I protease inhibitor by 
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the ~ppc~rance or nn enxymml¢ attivit~ (i,e, t~. 
llal~ctosid~sc) i~t¢~d or the disappearance or the pro- 
tease activity, This provides an intern|d control: a 
positive response (colour} is obtained onty when the 
protettse reaction is inhibited, All other possible In- 
terfering ~ctivides (e,B, inhibition of' MAb IGl2 bin- 
dins, non-specific proteulysis of gM-I|agl l0 or MAb 
IG 12, inhibition of/~.galactosidase activity, etc,) would 
result in a neliative response, Consequently, such an 
assay is particularly suitable for the screenins or corn- 
plex mixtures like microbial fermentation broths, where 
false positives are often a serious problem, 
However, tl~¢ detection system described here ctm be 
used to screen compounds from any origin for in- 
hibitory activity on HIV.I  protease. Tt~e assay is also 
relatively unaffected by low concentrations (5-10%) of 
organic solvents like methanol, acetonitrile or DM$O, 
a feature particularly useful when it is used to monitor 
the purification of an inhibitory activity, 
Using this detection system about 12 000 f'ermenta- 
tton broths were screened and several positives were 
found, One of these inhibitory activities was purified 
and identified as cz.MAPI [31]. This finding was largely 
unexpected since this compound, as expressed in its 
name, had been previously characterized as an inhibitor 
of alkaline proteases, with no activity on pepsin or 
other aspartic proteases [30]. Nevertheless, as shown in 
Fig. 4B, the inhibitory activity of ¢x-MAPI on HIV-I 
protease is comparable to pepstatin A, a characteristic 
inhibitor of aspartic proteases. 
As shown in Fig. 4A, c~-MAPI has a peptide-like 
structure with a C-terminal aldehyde group, like 
another natural product, tyrostatin, which has recently 
been reported to inhibit some acidic proteases [32]. In 
preliminary kinetic studies using purified HIV-I pro- 
tease and an HPLc assay based on a synthetic heptapep- 
tide as substmte [3J, =-MAPI was found to act as a non- 
competitive inhibitor (C. Tarnus, personal communica- 
tion). These observations suggested the direct involve. 
ment of the C-terminal aldehyde group in the inhibition 
mechanism. Such a prediction was confirmed by the 
loss of inhibitory activity on HIV-I protease observed 
after treating c~-MAPI with permanganate (S. Stella, 
unpublished results) in conditions known to cause the 
selective oxidation of the aldehyde to carboxylic acid 
[31]. 
Studies are currently in progress to elucidate the 
mechanism of inhibition of HIV-I protease by a- 
MAPI. At the same time other HIV-I protease in- 
hibitors found in microbial metabolites are being 
characterized, with the goal to find novel structures 
with improved in vitro and in vivo anti-HIV-I proper- 
ties. 
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